Department of Endocrinology, Yiyang Central Hospital, Yiyang, Hunan, 413000, China.
Department of Endocrinology, Air Force 986 Hospital, Xi'an, Shaanxi, 710054,China.
Complement Ther Med. 2020 Jan;48:102241. doi: 10.1016/j.ctim.2019.102241. Epub 2019 Nov 14.
Glucose disorders and dyslipidemia are closely associated with obesity and metabolic disease. The purpose of this study was to investigate the effect of Carnosine supplementation on lipid profile, fasting blood glucose, HbA1C and Insulin resistance.
MEDLINE/PubMed, Scopus and Web of sciences were investigated to identify relevant articles up to June 2019. The search strategy combined the Medical Subject Heading and Title and/or abstract keywords. The combined effect sizes were calculated as weight mean difference (WMD) using the random-effects model. Between study heterogeneity was evaluated by the Cochran's Q test and I.
Four RCTs studies investigated Carnosine use versus any control for at least 2 weeks were identified and analyzed. Overall results from the random-effects model on included studies, with 184 participants, indicated that carnosine intervention reduced HbA1C levels in intervention vs control groups (WMD: -0.92 %, 95 % CI: -1.20, -0.63, I:69 %). Four studies, including a total of 183 participants, reported TG changes as an outcome measure variable, but combined results did not show significant reduction in this outcome (WMD: -14.46 mg/dl, 95 % CI: -29.11, 0.19, I:94 %). Furthermore, combined results did not show any significant change in HOMA-IR, Cholesterol, fasting blood sugar, or HDL-C.
Carnosine supplementation results in a decrease in HbA1C, but elicits no effect on HOMA-IR, Cholesterol, fasting blood sugar, TG and HDL-C. Future studies with a larger sample sizes, varied doses of carnosine, and population-specific sub-groups are warranted to confirm, and enhance, the veracity of our findings.
葡萄糖代谢紊乱和血脂异常与肥胖和代谢性疾病密切相关。本研究旨在探讨肌肽补充对血脂谱、空腹血糖、HbA1C 和胰岛素抵抗的影响。
通过 MEDLINE/PubMed、Scopus 和 Web of Sciences 检索截至 2019 年 6 月的相关文献。检索策略结合了医学主题词和标题及/或摘要关键词。采用随机效应模型计算合并效应量为加权均数差（WMD）。采用 Cochran's Q 检验和 I ²评估研究间异质性。
共纳入 4 项 RCT 研究，分析了肌肽与任何对照至少 2 周的使用情况。对纳入研究的随机效应模型的总体结果，共纳入 184 名参与者，表明肌肽干预可降低干预组与对照组的 HbA1C 水平（WMD：-0.92%，95%CI：-1.20，-0.63，I：69%）。四项研究共纳入 183 名参与者，报告了 TG 变化作为结局测量变量，但合并结果显示该结局无显著降低（WMD：-14.46mg/dl，95%CI：-29.11，0.19，I：94%）。此外，HbA1C、HOMA-IR、胆固醇、空腹血糖或 HDL-C 也未发生显著变化。
肌肽补充可降低 HbA1C，但对 HOMA-IR、胆固醇、空腹血糖、TG 和 HDL-C 无影响。需要更大样本量、不同剂量肌肽和特定人群亚组的进一步研究来证实和增强我们的研究结果的准确性。
